Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting
of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) …

Background The antitumor efficacy of immune checkpoint inhibitors (ICIs) has increasingly
emerged during the last few years. However, there is a need to identify the safety profile of …

Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …

Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR
TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated …

Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have
become the frontier of cancer treatment and successfully prolonged the survival of patients …

Simple Summary In this article, we outline updates on the clinical development of savolitinib,
a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of …

Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective
MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant …